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Reply to the Editor:
There is no doubt that psychosocial issues
and social support systems are appropriate
considerations when evaluating potential
transplant recipients. Considering social
worth, on the other hand, is not justifiable.
I have read that the California prisoner in
the news stories died within a year after his
transplant, in part due to noncompliance.
That would not surprise Dr Richenbacher,
of course, in light of his comments.
But I wonder if we can make a blanket
assumption that no prisoner can be compli-
ant or that every prisoner cannot be ade-
quately available for postoperative fol-
low-up visits. Would not individual
consideration be warranted? Nelson Man-
dela may not be unique as a prisoner who
could be seriously considered for listing.
The status of prisoner, per se, should not
preclude consideration for transplantation,
in my view.
R. M. Sade, MD
Medical University of South Carolina
Department of Surgery
Suite 409, Box 250612
96 Jonathan Lucas St
Charleston, SC 29425
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Reply to the Editor:
I thank Dr Richenbacher for his thoughtful
letter. In an earlier, more naı¨ve version of
my life, I served as the surgeon at Minne-
sota’s maximum-security prison, a rotation
for University residents during the tenure
of the imaginative Owen Wangensteen. I
had a very positive experience with the
staff I worked with in the OR; they had
learned to be nurse anesthetists and radio-
logic or surgical technicians while serving
life sentences for crimes of passion against
unfaithful spouses or their consorts. I asked
their advice about whether prisoners should
be considered as possible altruistic kidney
donors. Then, as a resident member of the
transplant advisory committee, I advocated
allowing prisoners to donate kidneys as
good Samaritans. It worked beautifully, un-
til one day a paroled donor blackmailed the
recipient, threatening to take his kidney
back! I still advocate individual rather than
categorical judgments, so I support the
view that we shouldn’t accept or exclude
all prisoners from the complex social and
medical transaction of organ transplanta-
tion. However, the outcome of the Califor-
nia prisoner transplant described in Dr
Sade’s response and my youthful Minne-
sota experience argue for cautious conser-
vatism.
Martin McKneally, MD, PhD
University of Toronto
Department of Surgery
77 Forest Grove Dr
Toronto, Ontario M2K 1Z4, Canada
doi:10.1016/S0022-5223(03)00818-3
Indications for pulmonary
endarterectomy
To the Editor:
The recent article by Thistlethwaite and
colleagues1 could confuse nonsurgeons
caring for patients with chronic thrombo-
embolic pulmonary hypertension,2 espe-
cially if they become optimistic about pul-
monary endarterectomy after reading many
articles on the pioneering work from the
San Diego group.
Thistlethwaite and colleagues state
that the selection criteria for endarterec-
tomy included New York Heart Associa-
tion (NYHA) classes III and IV. Never-
theless, according to Table 1, 71 of 202
patients (35.1%) were in NYHA class I
or II! This deserves explanation. I would
never subject asymptomatic or very
lightly symptomatic patients to this type
of surgery, which carries considerable
morbidity and mortality. The same holds
true for patients with pulmonary vascular
resistance below 4 Wood units (320 dyn
· s · cm5).
In the 76 patients from group 1, the
surgeon found fresh (acute) thrombus in
the main lobar pulmonary arteries. In most
instances, fresh thrombus undergoes spon-
taneous lysis in anticoagulated patients; if
needed this resolution can be accelerated
by therapeutic thrombolysis. Simple embo-
lectomy, if ever, would be the appropriate
surgical intervention instead of endarterec-
tomy. Did these patients have chronic
thromboembolic pulmonary hypertension
at all? Were all of them treated with anti-
coagulants for at least 3 months? In pa-
tients adequately anticoagulated for 3
months, the presence of fresh thrombus in
their pulmonary arteries must be an abso-
lute rarity.3 The low operative mortality in
this group does not alone entitle the sur-
geon to operate; most probably the long-
term prognosis of these patients would be
just as good or better without surgery and
with anticoagulation alone.2
On the other extreme of the patient
spectrum, there are 7 patients (group 4)
with microscopic distal arterial vasculopa-
thy but without apparent thromboembo-
lism. In my opinion, this could be easily
identified by pulmonary angiography and
scintigraphy, and these patients should not
be subjected to endarterectomy.3 Why
were they operated on? The same probably
applies to patients with disease limited to
segmental arteries (group 3); even if end-
arterectomy can be achieved in these ves-
sels (each segment making up only about
5% of the cross-sectional area of the pul-
monary vascular bed), many segmental ar-
teries must be operated on to get a clini-
cally relevant result, making the operation
very demanding and risky.
Table 4 on perioperative mortality does
not correspond to the 1-month survival data
in Table 3. Probably morbidity instead of
mortality is described in Table 4; neverthe-
less, the table makes clear that there are
frequent and considerable complications of
the procedure, which underlies the neces-
sity to restrict endarterectomy only to pa-
tients who really need it and who might
benefit from it.
Benevolent indications for surgery re-
sult in great numbers of operated-on pa-
tients, often with statistically good results
(probably due in part to operations on less
sick patients) but with the dangers of un-
necessary morbidity and mortality just in
those less sick individuals. We cardiolo-
gists know this all too well from coronary
angioplasties and stent implantations. Be-
nevolent indications tend to discredit the
procedure so that it will not be offered to
patients who might really benefit from it.
Unless well-documented prospective stud-
ies persuade me otherwise, I will continue
to restrict the indication to pulmonary end-
arterectomy to severely limited patients
(NYHA class III or IV) without evidence
of improvement after 6 months of adequate
anticoagulation, who have a resting pulmo-
nary vascular resistance of more than 4
Wood units, resting mean pulmonary artery
pressure greater than 30 mm Hg, and bilat-
eral central (lobar and proximal) surgically
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accessible obstructions of more than 50%
of the pulmonary vascular bed.3
Martin Riedel, MD, FESC
German Heart Center
Lazarettstrasse 36
D-80636 Munich, Germany
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Reply to the Editor:
We appreciate the attention that Dr Riedel
has paid to our article. He brings up several
points that deserve clarification.
First, selection criteria for pulmonary
endarterectomy are multiple, and deter-
mination of candidacy for pulmonary
endarterectomy is based on a composite
of factors. Our selection criteria for sur-
gery include but are not limited to just
New York Heart Association (NYHA)
class III and IV patients. We offer pul-
monary endarterectomy to patients with
NYHA class I and II disease, although
only 1 in our series was in NYHA class I.
The long-term survival of patients with
untreated chronic thromboembolic pul-
monary hypertension, irrespective of
symptoms, is poor.1 In our hands, the
mortality associated with pulmonary end-
arterectomy (4.5%) is much less than the
published mortality associated with un-
treated thromboembolic pulmonary hy-
pertension (32.6% in 1 series with an
average follow-up of 18.7 months2). In
our experience, pulmonary endarterec-
tomy is not only associated with im-
proved long-term survival but also a bet-
ter quality of life for patients who
previously suffered from this disease.3
Furthermore, we have become increas-
ingly aware that the remaining open pul-
monary vascular bed after thromboem-
bolic occlusion can become irreparably
damaged by prolonged exposure to the
flow and pressure changes occasioned by
vascular occlusion in other areas.4 For
these reasons, we believe that pulmonary
endarterectomy should be offered to all
patients with thromboembolic pulmonary
hypertension, including those with less
clinical symptomatology.
Second, patients in group 1 of our
study were comprised of individuals with
chronic pulmonary hypertension who had
fibrotic thromboembolic obstruction of
their main and/or lobar pulmonary arter-
ies as well as fresh clot that occurred
either as a result of recurrent pulmonary
emboli or as a secondary consequence of
this obstructive process (see Figure 1).
No amount of anticoagulation or throm-
bolytic therapy would have altered the
distal fibrotic obstruction that was re-
sponsible for the patients’ pulmonary hy-
pertension. Incidentally, proximal clot
propagation occurs even in the setting of
therapeutic anticoagulation, as more than
80% of the group 1 patients referred to us
for operation had been on coumadin for a
period of longer than 3 months. We do
not treat patients with acute pulmonary
embolism with pulmonary endarterecto-
my; this is a different disease.
Third, although we have performed
more than 1600 pulmonary endarterecto-
mies in the last 10 years at the University
of California, San Diego, we still do not
have a completely foolproof method of
determining location of pulmonary vas-
cular obstructive disease in all patients.
We have found that pulmonary angiogra-
phy is the imaging modality that provides
the best preoperative assessment of
thromboembolic obstruction. However,
using a combination of assessments, in-
cluding angiography, angioscopy, venti-
lation-perfusion scanning, spiral com-
puted tomography (CT) scanning, and
3-dimensional CT angiography, there are
still a few patients in whom disease lo-
cation is not diagnosed with certainty
prior to surgery. It is precisely this small
group of patients (with distal small vessel
disease, or “primary” pulmonary hyper-
tension, type 4) that represent our treat-
ment failures and in retrospect would not
have been operated on. These patients,
incidentally, had failed other therapeutic
measures to reduce their pulmonary pres-
sures.
Fourth, Table 3 in our paper addresses
1-month survival data, while Table 4 lists
complications we have seen in the periop-
erative period after this operation. We re-
port complications we have seen with this
operation, and they represent a rate similar
to (or even less than) the complication rates
seen for other major cardiovascular opera-
tions. Rather than operating upon lower
risk patients, in recent years we have ex-
panded the eligible patient population for
pulmonary endarterectomy to include
older, sicker individuals, often with other
concomitant heart disease. In any event,
postoperative complications per se are not
a reason to exclude patients from a lifesav-
ing operation; rather, they represent an ac-
curate depiction of our clinical experience
with the surgical treatment of chronic
thromboembolic disease over a wide spec-
trum of patient age groups and disease se-
verity.
Finally, although comparisons be-
tween medically managed chronic throm-
boembolic disease and pulmonary endar-
terectomy have not been systematically
made in prospective randomized trials,
we believe that such trials would essen-
tially be unethical, given the disparity in
published survival statistics. The cumu-
lative data from our institution leave no
doubt that pulmonary endarterectomy is
the superior treatment choice for man-
agement of pulmonary hypertension
caused by chronic thromboembolic dis-
ease to the lungs.
Patricia A. Thistlethwaite, MD, PhD
Stuart W. Jamieson, MB, FRCS
Division of Cardiothoracic Surgery
University of California, San Diego
San Diego, CA 92103-8892
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